Sep 3, 2024 · Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the...

Nov 12, 2024 · Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly …

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.

Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases.

Jan 16, 2025 · The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' therapy to treat patients with a rare cancer that develops after organ or stem …

Jan 21, 2025 · About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and …

Jan 16, 2025 · About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and …

Jan 21, 2025 · THOUSAND OAKS, Calif., January 21, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus …

Jan 21, 2025 · Atara has entered into a non-binding term sheet with Redmile Group to provide up to $15 million in funding through an equity line of credit. Price Action: ATRA stock is down …